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Selection-related bias, an ongoing concern in doing
and publishing researchSelection is a phenomenon that epidemiology and clini-
cal researchers have been struggling with already long be-
fore the birth of clinical epidemiology as a formal
discipline, and it is expected to be a challenge also in the
future. An important reason is that the always developing
reality can never be completely observed and measured,
and that choices on what is being studied, analyzed, re-
ported, published, read, or taught will always be necessary.
But unavoidable and often useful selection does not need to
lead to selection bias. Another important reason to keep
paying attention to selection phenomena is therefore that
the methodology to prevent or reduce selection-related
biases in observations and conclusions must also develop
over time. Accordingly, we must be continuously aware
of new challenges in this area, to understand them, and to
work for ongoing methodological progress in the interest
of better internal and external validity and of good care
for patients. This has shown to be successful in the past
and contributed, for example, to better sampling methods
and measurements and to establishing the RCT,statistical
correction where possible, reporting guidelines, and trial
registers to reduce publication bias. The latter example
underlines that appropriately addressing selection phenom-
ena is also a matter of research intregrity [1].
An increasingly more recognized form of selection
that increases the risk for selection-related biases is
incomplete reporting of clinical research. In a systematic
review of a random sample of 300 trials, Bello and
co-workers evaluated incomplete reporting of the risk of un-
blinding. The authors concluded that only few published
articles on randomized trials reported risk of unblinding
,and that those who did were generally incomplete. They
discuss possible explanations and make recommendations
for improvement and further methodological research. In
another systematic review of randomized trials, Dibao-
Dina et al. studied the reporting of unequal randomization
and its scientific justification. They found that the random-
ization ratio was absent in more than half of the abstracts
of trials of unequal randomization, that its rationale was
not reported in more than 75% of the articles, and that
in a quarter of the studies unequal randomization was not
taken into account in sample size calculation. The in-
vestigators conclude that better reporting and justification
is needed. The more general question whether there is a0895-4356  2014 Elsevier Inc.
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using an online questionnaire sent to authors of published
reports of clinical trials and Cochrane systematic reviews
and other researchers, and a focus group of experienced re-
searchers and reviewers. While the response was low, selec-
tive (non-)publication of the respondents’ own work was
reported often. The researchers call for changes in current
practices of communicating trial results and
for systematic evaluation of measures to decrease publica-
tion bias.
The risk for selection-related bias, decreasing both ex-
ternal and internal validity of trials, is enhanced by poor pa-
tient recruitment and patient adherence [2]. Therefore,
interventions to improve recruitment adherence are also
themselves being investigated in trials. In this context, the
findings of Jeffery and her team are the more surprising
and important. Based on a review of randomized trials to
test interventions to improve patient adherence to medica-
tion, using a scale developed by the authors, they found that
even in these trials most adherence measurement and re-
cruitment methods were of low quality. Recommendations
are made to advance the quality of adherence research.
Selective follow-up observations are a common cause of
bias. Binder c.s. evaluated the extent to which ad hoc anal-
ysis of data with missing disease status because of death
may lead to bias in relative risk estimates. Using both simu-
lated and empirical examples, they describe the impact of
potential bias as to size and even direction of hazard ratio
estimates. This bias is not sufficiently recognized, and the
authors advise investigators to treat observed death cases
in cohort studies on a specific disease of interest with care.
Also, accurate methods for detection and identification
of candidates for further research or care are a cornerstone
in appropriately dealing with selection. To identify older
persons at increased risk of functional decline in primary
care, Suijker and her team modified and validated the Iden-
tification of Seniors at Risk (ISAR) screening question-
naire, also in comparison with risk stratification by age
alone. For this purpose, they used development and valida-
tion cohorts of community dwelling older people. Age, de-
pendence in instrumental activities of daily living, and
impaired memory were independently associated with
functional decline. They found the ISAR-PC (Primary
Care) to be of moderate predictive value but more effcient
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problem that the sensitivity of newborn screening on
medium-chain acyl-CoA dehydrogenase deficiency
(MCADD) cannot be estimated directly as only subjects
with a positive result ondergo a definitive test. They de-
signed a Bayesian model using prevalence data from
screening pilots, disease surveillance studies, and published
literature, and were able to assess the sensitivity of the
screening program (94%) and the percentage of additional
cases detected (47%) compared to non-screening. The au-
thors recommend using their approach also for other appli-
cations. In another paper on the detection of disease, Wu c.s.
report on the development and validation of algorithms of
locating patients with primary aldosteronism (PA), using
national health insurance reimbursement data and medical
charts from hospitals. It was found that an algorithm with
information on PA diagnosis and prescription of mineralo-
cortocoid receptor antagonist can locate PA patients in high
risk groups, and can be used to construct a PA sample for
research.
Speaking about selection, the most important concern is
that selection in the context of research, whether it would
be intended or nonintended, may make research less useful
for practice. To make sure that clinical research really con-
tributes to improve care, the worlds of research and practice
should therefore not be separated [3]. Raymond et al. con-
sidered the gap between clinical research and health care
practice. Based on a comprehensive analysis, they present
principles and methods of the ‘care trial’, that can identify
which medical alternative should be standard treatment and
at the same time provide optimal care in the presence or
uncertainty.
In order to bridge gaps beween research and practice, the
analysis of longitudinal data from prospective cohort stud-
ies should be able to distiguish between different develop-
mental trajectories. For this purpose,latent class analysis
(LCA) is increaslingly being used. In this context, Green
further elaborated on a previous paper [4] that suggested
caution in use of these methods. In a simulation study,
based on the imposed latent class structures in the previous
paper but with varying levels of randomly generated var-
iance, LCA performed well in identifying the simulated la-
tent class structure. The author discusses possible
explanations and implications. A good example of the dif-
ferent complex trajectories developing over time is the on-
set and change of multimorbidity patterns in older subjects.
Strauss et al. studied the use of LCA growth analysis in
understanding these trajectories in a dataset of primary care
consultations for 42 consensus-defined chronic morbidities
over three years, and tested the results in another primary
care dataset. A number of distinct trajectories were identi-
fied that were associated with poor health. The authors con-
clude that such trajectories must be incorporated in
studying the development of health and disease.To what extent is the hazard ratio (HR) informative for
clinical decision making? Cortes et al. considered that from
a patient care point of view, the ratio of median survival
times, the median ratio (MR), may be more informative
than the HR. Based on a reanalysis of cancer survival ar-
ticles published in the New England Journal of Medicine
between 2000 and 2010, they evaluated the empirical con-
cordance between the HR and the MR. It was found that the
average concordance allows to approximate HR from MR
to determine sample size, but given the large disconcord-
ance limits the two ratios are not interchangeable. There-
fore the authors recommend to attach descriptive survival
measures to the HR.
For efficiently evaluating the effectiveness of interven-
tions, the factorial design can be considered. This design al-
so enables the evaluation of possible interaction between
interventions. Mdege c.s. reviewed the use and study re-
porting of this design at the cluster level, including studies
evaluating at least one complex intervention. It was found
that the 2x2 cluster randomized controlled factorial trial de-
sign has been used in a wide range of health care settings,
mainly to minimize contamination, to evaluate two inter-
ventions in the same study, and to study interactions. How-
ever, the quality of the trials was often insufficient or
insufficiently reported. The authors emphasize the need
for reporting guidelines.
As cost-effectivess is increasingly used as a criterion by
decision makers, acceptable validity of models to evaluate
it is of great societal importance. Based on a review of iden-
tified cost-effectiveness models of pharmacologic stroke
prevention in atrial fibrillation (SPAF), Limone and
co-workers found that, while pharmacologic SPAF trials
have been extensively reported, many of these have flaws.
Although almost all models included warfarin, only 60%
assessed the impact of warfarin control on conclusions.
Many other observations of concern were reported. The au-
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